These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 33508404)
1. In-vitro pharmacokinetic/pharmacodynamic model data suggest a potential role of new formulations of posaconazole against Candida krusei but not Candida glabrata infections. Beredaki MI; Arendrup MC; Mouton JW; Meletiadis J Int J Antimicrob Agents; 2021 Mar; 57(3):106291. PubMed ID: 33508404 [TBL] [Abstract][Full Text] [Related]
2. Voriconazole efficacy against Candida glabrata and Candida krusei: preclinical data using a validated in vitro pharmacokinetic/pharmacodynamic model. Beredaki MI; Georgiou PC; Siopi M; Kanioura L; Arendrup MC; Mouton JW; Meletiadis J J Antimicrob Chemother; 2020 Jan; 75(1):140-148. PubMed ID: 31665417 [TBL] [Abstract][Full Text] [Related]
3. The Role of New Posaconazole Formulations in the Treatment of Candida albicans Infections: Data from an Beredaki MI; Arendrup MC; Andes D; Mouton JW; Meletiadis J Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33468486 [TBL] [Abstract][Full Text] [Related]
4. Candida and candidaemia. Susceptibility and epidemiology. Arendrup MC Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246 [TBL] [Abstract][Full Text] [Related]
5. Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for Candida albicans Using a Validated Beredaki MI; Georgiou PC; Siopi M; Kanioura L; Andes D; Arendrup MC; Mouton JW; Meletiadis J Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32229492 [TBL] [Abstract][Full Text] [Related]
6. Development of an in vitro pharmacokinetic/pharmacodynamic model in the presence of serum for studying micafungin activity against Candida albicans: a need for revision of CLSI susceptibility breakpoints. Beredaki MI; Arendrup MC; Andes D; Meletiadis J J Antimicrob Chemother; 2023 Jun; 78(6):1386-1394. PubMed ID: 37071557 [TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacodynamics and dose optimization of liposomal amphotericin B against Beredaki M-I; Arendrup MC; Pournaras S; Meletiadis J Antimicrob Agents Chemother; 2024 Aug; 68(8):e0022524. PubMed ID: 38958455 [TBL] [Abstract][Full Text] [Related]
8. [Comparison of Clinical Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution methods for determining the susceptibilities of Candida isolates]. Dalyan Cilo B; Topaç T; Ağca H; Sağlam S; Efe K; Ener B Mikrobiyol Bul; 2018 Jan; 52(1):35-48. PubMed ID: 29642828 [TBL] [Abstract][Full Text] [Related]
10. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Pfaller MA; Rinaldi M; Rodriguez-Tudela JL; Verweij PE J Clin Microbiol; 2005 Aug; 43(8):3884-9. PubMed ID: 16081926 [TBL] [Abstract][Full Text] [Related]
11. Evaluating posaconazole dosing regimens of the different formulations against Aspergillus spp. in adults: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation. Wei XC; Zhao MF; Li X; Xiao X Int J Antimicrob Agents; 2020 Oct; 56(4):106112. PubMed ID: 32721598 [TBL] [Abstract][Full Text] [Related]
13. Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model. Siopi M; Mavridou E; Mouton JW; Verweij PE; Zerva L; Meletiadis J J Antimicrob Chemother; 2014 Jun; 69(6):1611-9. PubMed ID: 24550381 [TBL] [Abstract][Full Text] [Related]
14. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance]. Karabıçak N; Alem N Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336 [TBL] [Abstract][Full Text] [Related]
15. Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp. Pfaller MA; Castanheira M; Messer SA; Rhomberg PR; Jones RN Diagn Microbiol Infect Dis; 2014 Jun; 79(2):198-204. PubMed ID: 24736096 [TBL] [Abstract][Full Text] [Related]
16. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland. Orasch C; Marchetti O; Garbino J; Schrenzel J; Zimmerli S; Mühlethaler K; Pfyffer G; Ruef C; Fehr J; Zbinden R; Calandra T; Bille J; Clin Microbiol Infect; 2014 Jul; 20(7):698-705. PubMed ID: 24188136 [TBL] [Abstract][Full Text] [Related]
17. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods. Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252 [TBL] [Abstract][Full Text] [Related]
18. In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei. Drago M; Scaltrito MM; Morace G; Eur J Clin Microbiol Infect Dis; 2004 Aug; 23(8):619-24. PubMed ID: 15258831 [TBL] [Abstract][Full Text] [Related]